← Back to All US Stocks

Align Technology Inc. (ALGN) Stock Fundamental Analysis & AI Rating 2026

ALGN Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies DE CIK: 0001097149
Updated This Month • Analysis: May 7, 2026 • SEC Data: 2026-03-31
Combined AI Rating
BUY
73% Confidence
AGREEMENT
HOLD
72% Conf
BUY
74% Conf

📊 ALGN Key Takeaways

Revenue: $1.0B
Net Margin: 10.8%
Free Cash Flow: $120.3M
Current Ratio: 1.39x
Debt/Equity: 0.00x
EPS: $1.57
AI Rating: HOLD with 72% confidence
Align Technology Inc. (ALGN) receives a BUY rating with 73% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $1.0B, net profit margin of 10.8%, and return on equity (ROE) of 2.7%, Align Technology Inc. demonstrates strong fundamentals in the Healthcare sector. Below is our complete ALGN stock analysis for 2026.

Is Align Technology Inc. (ALGN) a Good Investment?

Claude

Align Technology demonstrates financial stability with a fortress balance sheet, zero debt, and consistent free cash flow generation, but faces fundamental growth challenges with revenue growth of just 0.9% YoY and concerning low returns on capital (ROE 2.7%, ROA 1.8%), suggesting potential market saturation in its core orthodontic business.

ChatGPT

Align Technology shows solid underlying fundamentals with high gross margins, positive free cash flow generation, and a debt-free balance sheet supported by over $1 billion in cash. Profitability remains healthy, but the latest period shows only modest revenue growth and slightly lower net income, which suggests the business is financially strong but not currently in a high-growth phase. Overall, the company appears fundamentally resilient with good earnings quality, though future upside depends on reaccelerating growth while preserving margins.

Why Buy Align Technology Inc. Stock? ALGN Key Strengths

Claude
  • + Exceptional 70.8% gross margins indicating strong pricing power and operational efficiency in orthodontic appliances
  • + Zero debt with $1.1B cash position and 1.39x current ratio providing financial flexibility and stability
  • + Consistent free cash flow generation of $120.3M (11.6% FCF margin) enabling self-funding and potential shareholder returns
ChatGPT
  • + High gross margin of 67.2% supports strong unit economics
  • + Debt-free capital structure and strong liquidity reduce financial risk
  • + Free cash flow of $490.78M demonstrates solid cash conversion and operating discipline

ALGN Stock Risks: Align Technology Inc. Investment Risks

Claude
  • ! Stagnant revenue growth of just 0.9% YoY signals market saturation or competitive pressures in core Invisalign product line
  • ! Severely depressed return metrics (ROE 2.7%, ROA 1.8%) indicate inefficient capital deployment and poor capital allocation decisions
  • ! Operating margin compression (13.6%) relative to gross margin (70.8%) suggests rising SG&A and operating expense burdens
ChatGPT
  • ! Revenue growth of only 0.9% suggests limited near-term expansion momentum
  • ! Net income declined 2.6% year over year, indicating some pressure on bottom-line growth
  • ! ROE of 10.1% is respectable but not especially strong for a premium medical technology business

Key Metrics to Watch

Claude
  • * Revenue growth trajectory - need evidence of market expansion or new product adoption beyond core Invisalign
  • * Return on equity and return on assets - critical to understand if capital deployment improves efficiency
  • * Free cash flow deployment strategy - capital allocation decisions with dividends, buybacks, M&A, or R&D investments
ChatGPT
  • * Revenue growth and case volume expansion
  • * Operating margin and free cash flow margin

Align Technology Inc. (ALGN) Financial Metrics & Key Ratios

Revenue
$1.0B
Net Income
$112.8M
EPS (Diluted)
$1.57
Free Cash Flow
$120.3M
Total Assets
$6.3B
Cash Position
$1.1B

💡 AI Analyst Insight

Align Technology Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

ALGN Profit Margin, ROE & Profitability Analysis

Gross Margin 70.8%
Operating Margin 13.6%
Net Margin 10.8%
ROE 2.7%
ROA 1.8%
FCF Margin 11.6%

ALGN vs Healthcare Sector: How Align Technology Inc. Compares

How Align Technology Inc. compares to Healthcare sector averages

Net Margin
ALGN 10.8%
vs
Sector Avg 12.0%
ALGN Sector
ROE
ALGN 2.7%
vs
Sector Avg 15.0%
ALGN Sector
Current Ratio
ALGN 1.4x
vs
Sector Avg 2.0x
ALGN Sector
Debt/Equity
ALGN 0.0x
vs
Sector Avg 0.6x
ALGN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Align Technology Inc. Stock Overvalued? ALGN Valuation Analysis 2026

Based on fundamental analysis, Align Technology Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
2.7%
Sector avg: 15%
Net Profit Margin
10.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Align Technology Inc. Balance Sheet: ALGN Debt, Cash & Liquidity

Current Ratio
1.39x
Quick Ratio
1.28x
Debt/Equity
0.00x
Debt/Assets
34.3%
Interest Coverage
2,783.43x
Long-term Debt
N/A

ALGN Revenue & Earnings Growth: 5-Year Financial Trend

ALGN 5-year financial data: Year 2021: Revenue $4.0B, Net Income $442.8M, EPS $5.53. Year 2022: Revenue $4.0B, Net Income $1.8B, EPS $22.41. Year 2023: Revenue $4.0B, Net Income $772.0M, EPS $9.69. Year 2024: Revenue $4.0B, Net Income $361.6M, EPS $4.61. Year 2025: Revenue $4.0B, Net Income $445.1M, EPS $5.81.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Align Technology Inc.'s revenue has shown modest growth of 2% over the 5-year period. The most recent EPS of $5.81 reflects profitable operations.

ALGN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
11.6%
Free cash flow / Revenue

ALGN Quarterly Earnings & Performance

Quarterly financial performance data for Align Technology Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $979.3M $93.2M $1.27
Q3 2025 $977.9M $56.8M $0.78
Q2 2025 $1.0B $96.6M $1.28
Q1 2025 $979.3M $93.2M $1.27
Q3 2024 $960.2M $116.0M $1.55
Q2 2024 $1.0B $96.6M $1.28
Q1 2024 $943.1M $87.8M $1.14
Q3 2023 $890.3M $72.7M $0.93

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Align Technology Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$151.0M
Cash generated from operations
Stock Buybacks
$31.2M
Shares repurchased (TTM)
Capital Expenditures
$30.8M
Investment in assets
Dividends
None
No dividend program

ALGN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Align Technology Inc. (CIK: 0001097149)

📋 Recent SEC Filings

Date Form Document Action
May 6, 2026 10-Q algn-20260331.htm View →
May 1, 2026 8-K algn-20260430.htm View →
Apr 29, 2026 8-K algn-20260429.htm View →
Apr 7, 2026 DEF 14A algn-20260407.htm View →
Feb 27, 2026 10-K algn-20251231.htm View →

Frequently Asked Questions about ALGN

What is the AI rating for ALGN?

Align Technology Inc. (ALGN) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 73% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are ALGN's key strengths?

Claude: Exceptional 70.8% gross margins indicating strong pricing power and operational efficiency in orthodontic appliances. Zero debt with $1.1B cash position and 1.39x current ratio providing financial flexibility and stability. ChatGPT: High gross margin of 67.2% supports strong unit economics. Debt-free capital structure and strong liquidity reduce financial risk.

What are the risks of investing in ALGN?

Claude: Stagnant revenue growth of just 0.9% YoY signals market saturation or competitive pressures in core Invisalign product line. Severely depressed return metrics (ROE 2.7%, ROA 1.8%) indicate inefficient capital deployment and poor capital allocation decisions. ChatGPT: Revenue growth of only 0.9% suggests limited near-term expansion momentum. Net income declined 2.6% year over year, indicating some pressure on bottom-line growth.

What is ALGN's revenue and growth?

Align Technology Inc. reported revenue of $1.0B.

Does ALGN pay dividends?

Align Technology Inc. does not currently pay dividends.

Where can I find ALGN SEC filings?

Official SEC filings for Align Technology Inc. (CIK: 0001097149) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is ALGN's EPS?

Align Technology Inc. has a diluted EPS of $1.57.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is ALGN a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, Align Technology Inc. has a BUY rating with 73% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.

Is ALGN stock overvalued or undervalued?

Valuation metrics for ALGN: ROE of 2.7% (sector avg: 15%), net margin of 10.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy ALGN stock in 2026?

Our dual AI analysis gives Align Technology Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is ALGN's free cash flow?

Align Technology Inc.'s operating cash flow is $151.0M, with capital expenditures of $30.8M. FCF margin is 11.6%.

How does ALGN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin 10.8% (avg: 12%), ROE 2.7% (avg: 15%), current ratio 1.39 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% DT 92% DECK 92% DAVEW 92% ANET 88% RDDT 88% KNSL 88% MGRE 88%
Sector: All Healthcare Stocks →
Browse: Buy Stocks
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 7, 2026 | Data as of: 2026-03-31 | Powered by Claude AI